Lu

Lutetium

Supply Chain

Lutetium Supply Chain: From Mine to Market

Lutetium is the rarest naturally occurring lanthanide and follows the rare earth supply chain with China controlling ~95% of production. Separation of lutetium requires the most stages of solvent extraction of any rare earth due to its position at the end of the lanthanide series. Global production is only ~10 tonnes/year. Two emerging medical applications are driving increased interest: LSO/LYSO scintillation crystals for PET scanners (every modern PET scanner uses lutetium-based detectors) and Lu-177 radiopharmaceuticals for targeted cancer therapy. Novartis Pluvicto (Lu-177 PSMA for prostate cancer, >$1B annual sales) has made lutetium strategically important for the pharmaceutical industry.

Annual Production

10

tonnes

Top Producer

China

95% of global output

Global Reserves

Part of total REE reserves (rarest lanthanide)

Recycling Rate

0%

End-of-life recycling

Production Geography

Global Lutetium production is led by China, which accounts for approximately 95% of world output, followed by Myanmar. The full list of major producing nations includes China, Myanmar, Australia. This geographic concentration means that disruptions in key producing regions can have outsized impacts on global supply and pricing.

Extraction Methods

Lutetium is extracted using the following primary methods:

  • Ion-adsorption clay leaching
  • Byproduct of heavy REE separation

Processing and Intermediate Products

Lutetium is primarily sourced from Ion-adsorption clays, Xenotime. After extraction, the raw material undergoes multiple processing steps including beneficiation, chemical treatment, and refining to reach the purity levels required by downstream industries. Typical ore grades range from 0.001-0.005% Lu2O3.

Key Supply Chain Participants

The Lutetium supply chain involves these major companies:

China Southern Rare Earth Group

Producer
China

Primary global source of separated lutetium

Siemens Healthineers

Major consumer SHL.DE
Germany

Major PET scanner manufacturer using LSO/LYSO scintillation crystals containing lutetium

GE HealthCare

Major consumer GEHC
United States

Produces PET scanners using lutetium-based scintillator detectors

Novartis

Consumer NVS
Switzerland

Markets Pluvicto (lutetium-177 PSMA), a radioligand therapy for metastatic prostate cancer approved in 2022

Supply Chain Vulnerabilities

Key vulnerabilities in the Lutetium supply chain include concentration of 95% of production in China, limited processing capacity diversification, and long lead times for new mining projects. The high supply risk rating reflects the severity of these concentration risks and the difficulty of rapidly establishing alternative supply sources.

Return to the Lutetium hub page or browse the full Mineral Library.